Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kallen Schwark"'
Autor:
Kallen Schwark, Dana Messinger, Jessica R. Cummings, Joshua Bradin, Abed Kawakibi, Clarissa M. Babila, Samantha Lyons, Sunjong Ji, Rodrigo T. Cartaxo, Seongbae Kong, Evan Cantor, Carl Koschmann, Viveka Nand Yadav
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Pediatric high-grade glioma (pHGG), including both diffuse midline glioma (DMG) and non-midline tumors, continues to be one of the deadliest oncologic diagnoses (both henceforth referred to as “pHGG”). Targeted therapy options aimed at key oncoge
Externí odkaz:
https://doaj.org/article/3bb16868598048f6a234870833468b8a
Autor:
Lisa Mayr, Maria Trissal, Kallen Schwark, Jenna Labelle, Andrew Groves, Julia Furtner-Srajer, Jeffrey Supko, Liesa Weiler-Wichtl, Olivia Hack, Jacob Rozowsky, Joana G. Marques, Eshini Pandatharatna, Ulrike Leiss, Verena Rosenmayr, Frank Dubois, Noah F. Greenwald, Sibylle Madlener, Armin S. Guntner, Hana Pálová, Natalia Stepien, Daniela Lötsch-Gojo, Christian Dorfer, Karin Dieckmann, Andreas Peyrl, Amedeo A. Azizi, Alicia Baumgartner, Ondřej Slabý, Petra Pokorná, Pratiti Bandopadhayay, Rameen Beroukhim, Keith Ligon, Christof Kramm, Annika Bronsema, Simon Bailey, Ana Guerreiro Stücklin, Sabine Mueller, David T. Jones, Natalie Jäger, Jaroslav Štěrba, Leonhard Müllauer, Christine Haberler, Chandan Kumar-Sinha, Arul Chinnaiyan, Rajen Mody, Mary Skrypek, Nina Martinez, Daniel C. Bowers, Carl Koschmann, Johannes Gojo, Mariella Filbin
Publikováno v:
Cancer Research. 83:5719-5719
PDGFRA has been shown to be commonly altered in high-grade gliomas (HGGs), including histone 3 lysine 27-mutated diffuse midline gliomas (H3K27M DMG), a disease with almost no long-term survivors. Here, we performed comprehensive genomic and transcri
Autor:
Lisa Mayr, Maria Trissal, Kallen Schwark, Jenna Labelle, Seongbae Kong, Andrew Groves, Jeffrey Supko, Olivia Hack, Joana Marques, Eshini Panditharatna, Frank Dubois, Noah Greenwald, Pratiti Bandopadhayay, Keith Ligon, Julia Furtner-Srajer, Liesa Weiler-Wichtl, Ulrike Leiss, Verena Rosenmayr, Sibylle Madlener, Natalia Stepien, Daniela Lötsch-Gojo, Christian Dorfer, Karin Dieckmann, Amedeo Azizi, Armin Guntner, Hana Palova, Ondrej Slaby, Petra Pokorná, Rameen Beroukhim, Christof Kramm, David T Jones, Jaroslav Štěrba, Leonhard Mullauer, Christine Haberler, Nisha Perez, Sean Kim, Anthony Hsieh, Sasa Dimitrijevic, Mary Skrypek, Nina Martinez, Daniel Bowers, Mariella Filbin, Johannes Gojo, Carl Koschmann
Publikováno v:
Neuro-Oncology. 24:vii103-vii103
Pediatric high-grade glioma (pHGG) is an incurable disease with a median survival of less than 6 months post-progression and no effective targeted therapy. PDGFRA is commonly altered in pHGG, but targeting PDGFRA in this disease has been unsuccessful
Dynamic microRNA activity identifies therapeutic targets in trastuzumab‐resistant HER2+breast cancer
Autor:
Rachel B. Blaisdell, Matthew Hall, Lonnie D. Shea, Kallen Schwark, Joseph T. Decker, Jacqueline S. Jeruss
Publikováno v:
Biotechnology and Bioengineering. 115:2613-2623
MicroRNAs (miRNAs) are implicated in numerous physiologic and pathologic processes, such as the development of resistance to chemotherapy. Determining the role of miRNAs in these processes is often accomplished through measuring miRNA abundance by po
Autor:
Joseph T, Decker, Matthew S, Hall, Rachel B, Blaisdell, Kallen, Schwark, Jacqueline S, Jeruss, Lonnie D, Shea
Publikováno v:
Biotechnology and bioengineering. 115(10)
MicroRNAs (miRNA) are implicated in numerous physiologic and pathologic processes, such as the development of resistance to chemotherapy. Determining the role of miRNAs in these processes is often accomplished through measuring miRNA abundance by PCR
Autor:
Arul M. Chinnaiyan, Amy L. Pasternak, Marcia Leonard, Patricia L. Robertson, Carl Koschmann, Bernard L. Marini, Kallen Schwark, Sylvia G. Escolero, Amy K. Bruzek, Chandan Kumar-Sinha, Rajen Mody
Publikováno v:
Neuro-Oncology. 21:ii87-ii87
BACKGROUND: Pediatric diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG) have an average progression-free survival (PFS) of 3 months. Gene fusions in cancer are being targeted with promising results. However, targeting fusi